arrow
A

Angela M. Minassian

University of Oxford
H指数:54
被引数:2.1万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Addition of blood-stage antibody enhances anti-sporozoite antibody protection in a humanized mouse model of Plasmodium falciparum infection

在恶性疟原虫感染的人源化小鼠模型中,血阶段抗体增强抗子孢子抗体的保护作用

2026-06-220
OAAI
B and T cell responses to pre-erythrocytic R21/Matrix-M and blood-stage RH5.1/Matrix-M malaria vaccines in endemic settings

B和T细胞对流行病学设置中红细胞前期R21/Matrix-M和红细胞期RH5.1/Matrix-M疟疾疫苗的应答

2026-03-040
OA
SARS-CoV-2-Specific Immune Responses to Vaccination in Children and Adolescents with Suppressed Immune Systems: A Prospective, Observational Study

SARS-CoV-2特异性疫苗接种免疫反应:免疫抑制儿童及青少年的前瞻性、观察性研究

2025-10-240
OAAI
Development of clinical immunity to Plasmodium vivax following repeat controlled human malaria infection

重复受控人体疟疾感染后对 *Plasmodium vivax* 的临床免疫发展

2025-09-250
OAAI
Heterologous COVID-19 vaccine schedule with protein-based prime (NVX-CoV2373) and mRNA boost (BNT162b2) induces strong humoral responses: Results from COV-BOOST trial

蛋白为基础的初次免疫(NVX-CoV2373)与mRNA加强免疫(BNT162b2)的异源COVID-19疫苗接种方案可诱导强烈的体液免疫反应:COV-BOOST试验结果

2025-08-070
OAAI
Risk analysis for outpatient experimental infection as a pathway for affordable RSV vaccine development

门诊实验性感染的风险分析作为一种开发可负担RSV疫苗的途径

2025-04-150
OA
Plasmodium falciparum infection induces T cell tolerance that is associated with decreased disease severity upon re-infection

恶性疟原虫感染诱导T细胞耐受,该耐受与再感染时疾病严重程度降低相关。

2025-04-111
OA
Blood-stage malaria vaccine candidate RH5.1/Matrix-M in healthy Tanzanian adults and children; an open-label, non-randomised, first-in-human, single-centre, 1b trial
2024-10-017
OAAI
Preclinical development of a stabilized RH5 virus-like particle vaccine that induces improved antimalarial antibodies
2024-07-013
OAAI
Analyses of human vaccine-specific circulating and bone marrow-resident B cell populations reveal benefit of delayed vaccine booster dosing with blood-stage malaria antigens
2024-01-172
OAAI
Superior antibody immunogenicity of a viral-vectored RH5 blood-stage malaria vaccine in Tanzanian infants as compared to adults
MED
IF11.8
2023-10-0115
OA
Reactogenicity, immunogenicity and breakthrough infections following heterologous or fractional second dose COVID-19 vaccination in adolescents (Com-COV3): A randomised controlled trial

青少年 (Com-COV3) 异源或分段第二次剂量新型冠状病毒肺炎疫苗接种后的反应原性、免疫原性和突破性感染: 一项随机对照试验

2023-09-015
OAAI
Vaccination with Plasmodium vivax Duffy-binding protein inhibits parasite growth during controlled human malaria infection
2023-07-1216
OAAI
Persistence of immune responses after heterologous and homologous third COVID-19 vaccine dose schedules in the UK: eight-month analyses of the COV-BOOST trial

英国异源和同源第三新型冠状病毒肺炎疫苗给药方案后免疫反应的持久性: cov-boost试验的八个月分析

2023-07-0115
OAAI
Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial (vol 84, pg 795, 2022)

在英国两剂ChAdOx1 nCov-19或BNT162b2后,作为第三剂加强剂给予七种新型冠状病毒肺炎疫苗后的免疫原性持久性: COV-BOOST试验的三个月分析 (第84卷,795页,2022页)

2023-05-011
OAAI
Delayed boosting improves human antigen-specific Ig and B cell responses to the RH5.1/AS01B malaria vaccine
2023-01-2414
OA